down arrow

Organovo Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68620A2033
USD
2.29
0.17 (8.02%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.162.40

52 Week

1.4121.96
Valuation
Technical
Day's Volume

CASH

117.49 k

Shareholding (Jun 2025)

FII

0.06%

Held by 9 FIIs

DII

98.03%

Held by 2 DIIs

Promoter

0.00%

How big is Organovo Holdings, Inc.?

22-Jun-2025

As of Jun 18, Organovo Holdings, Inc. has a market capitalization of 3.93 million, with net sales of 0.14 million and a net profit of -2.49 million over the latest four quarters. Shareholder's funds are reported at 10.49 million, and total assets amount to 14.65 million.

As of Jun 18, Organovo Holdings, Inc. has a market capitalization of 3.93 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.14 million, while the sum of Net Profit for the same period is -2.49 million.<BR><BR>As of Mar 25, the Shareholder's Funds are reported at 10.49 million, and the Total Assets amount to 14.65 million.

Read More

What does Organovo Holdings, Inc. do?

22-Jun-2025

Organovo Holdings, Inc. is a commercial-stage biotechnology company focused on developing functional human tissues. As of March 2025, it reported net sales of $0 million and a net profit of $7 million, with a market cap of $3.93 million.

Overview:<BR>Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 3.93 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.02<BR>- Return on Equity: -23.71%<BR>- Price to Book: 0.37<BR><BR>Contact Details:<BR>- Address: 440 Stevens Avenue, Suite 200, SOLANA BEACH CA: 92075<BR>- Tel: ['1 858 2241000', '1 858 2241092']<BR>- Fax: 1 302 6365454<BR>- Website: http://organovo.com/

Read More

Who are in the management team of Organovo Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Organovo Holdings, Inc. includes Mr. Keith Murphy as Executive Chairman and Principal Executive Officer, along with independent directors Mr. Douglas Cohen, Mr. David Gobel, Ms. Alison Milhous, and Mr. Adam Stern.

As of March 2022, the management team of Organovo Holdings, Inc. includes Mr. Keith Murphy, who serves as the Executive Chairman and Principal Executive Officer. Additionally, the board of directors features several independent directors: Mr. Douglas Cohen, Mr. David Gobel, Ms. Alison Milhous, and Mr. Adam Stern.

Read More

Is Organovo Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of May 10, 2023, Organovo Holdings, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to weak financial metrics and significant underperformance compared to peers and the S&P 500.

As of 10 May 2023, Organovo Holdings, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.30, an EV to EBIT of 0.60, and an EV to EBITDA of 0.61, which suggest that while the company has low valuations relative to its earnings potential, the overall financial health remains concerning.<BR><BR>In comparison to its peers, Organovo's valuation metrics are less favorable; for instance, Frequency Therapeutics, Inc. has a P/E ratio of -1.3504 and an EV to EBITDA of -0.0590, while Surrozen, Inc. shows a P/E of 6.4924 and an EV to EBITDA of 0.8737. These comparisons highlight that Organovo's financial standing is not only weak but also that it does not qualify for a standard valuation assessment. Furthermore, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -73.36% compared to the index's 2.44%, reinforcing the notion that it is overvalued in the current market context.

Read More

Is Organovo Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Organovo Holdings, Inc. shows a neutral trend with mixed signals: mildly bullish MACD and Dow Theory on both weekly and monthly time frames, but bearish daily moving averages, indicating a lack of strong momentum.

As of 9 September 2025, the technical trend for Organovo Holdings, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bullish weekly outlook but a mildly bearish monthly perspective. The KST is bullish weekly but bearish monthly, and the Dow Theory supports a mildly bullish position on both time frames. However, the daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.89

stock-summary
Return on Equity

-20.83%

stock-summary
Price to Book

0.68

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.13%
0%
-9.13%
6 Months
29.01%
0%
29.01%
1 Year
-59.41%
0%
-59.41%
2 Years
-84.73%
0%
-84.73%
3 Years
-87.45%
0%
-87.45%
4 Years
-95.66%
0%
-95.66%
5 Years
-97.65%
0%
-97.65%

Organovo Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Organovo Holdings, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Organovo Holdings, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish trend on both weekly and monthly time frames, while the Bollinger Bands indicate a mildly bullish weekly outlook but a mildly bearish monthly perspective. The KST is bullish weekly but bearish monthly, and the Dow Theory supports a mildly bullish position on both time frames. However, the daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction. There is no available return data to compare the company's performance against the S&P 500....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-38.01%
EBIT Growth (5y)
5.46%
EBIT to Interest (avg)
-14.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.23%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.30
EV to EBIT
0.60
EV to EBITDA
0.61
EV to Capital Employed
7.53
EV to Sales
-7.53
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1261.60%
ROE (Latest)
-23.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.91%)

Foreign Institutions

Held by 9 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.15% vs 17.50% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-3.30",
          "chgp": "12.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-3.30",
          "chgp": "15.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-78,783.80%",
          "val2": "-86,820.50%",
          "chgp": "803.67%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs -75.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 82.99% vs 15.03% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.30",
          "val2": "-14.80",
          "chgp": "16.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-14.70",
          "chgp": "82.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-87,611.10%",
          "val2": "-138,403.70%",
          "chgp": "5,079.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.90
-3.30
12.12%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.80
-3.30
15.15%
Operating Profit Margin (Excl OI)
-78,783.80%
-86,820.50%
803.67%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 15.15% vs 17.50% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-12.30
-14.80
16.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.50
-14.70
82.99%
Operating Profit Margin (Excl OI)
-87,611.10%
-138,403.70%
5,079.26%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs -75.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 82.99% vs 15.03% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Organovo Holdings, Inc. stock-summary
stock-summary
Organovo Holdings, Inc.
Pharmaceuticals & Biotechnology
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Company Coordinates stock-summary
Company Details
440 Stevens Avenue, Suite 200 , SOLANA BEACH CA : 92075
stock-summary
Tel: 1 858 22410001 858 2241092
stock-summary
http://organovo.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."